Wu Y, et al. - Experts conducted this systematic review and meta-analysis to evaluate the effect of phosphodiesterase type 5 inhibitors (PDE5-Is) use on the risk of prostate cancer and biochemical recurrence (BCR) in patients with prostate cancer. To identify eligible studies that assessed the effects of PDE5-IS use on prostate cancer risk as well as BCR in patients with prostate cancer, they conducted a search of the PubMed, Web of Science, and Medline databases. A total of nine studies met inclusion criteria and were included in the analysis. According to findings, PDE5-Is use and the increased risk of prostate cancer were not associated. Furthermore, in prostate cancer patients with erectile dysfunction following radical prostatectomy or radiation therapy, PDE5-Is use was not linked to BCR risk. Moderate heterogeneity across studies was suggested in the heterogeneity test. The risk of prostate cancer and BCR in prostate cancer patients was not influenced by PDE5-Is use.